Trinity Biotech (TRIB) Revenue (2009 - 2024)

Trinity Biotech has disclosed Revenue across 16 years of filings, most recently posting $15.9 million for Q4 2024.

• Revenue for Q4 2024 came in at $15.9 million, up 18.09% year-over-year; the trailing twelve-month figure through Dec 2024 was $61.6 million (up 8.31% YoY), and the FY2025 annual result was $43.8 million, down 28.87% from the prior year.
• Revenue came in at $15.9 million for Q4 2024 at Trinity Biotech, up from $15.2 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $32.8 million in Q4 2020 to a low of $13.4 million in Q4 2023.
• The 5-year median for Revenue is $15.8 million (2022), against an average of $18.8 million.
• Peak annual rise in Revenue reached 61.28% in 2021, while the deepest fall reached 40.41% in 2021.
• Trinity Biotech's Revenue stood at $32.8 million in 2020, then sank by 40.41% to $19.5 million in 2021, then retreated by 19.46% to $15.7 million in 2022, then fell by 14.61% to $13.4 million in 2023, then gained by 18.09% to $15.9 million in 2024.
• The last three Revenue figures came in at $15.9 million (Q4 2024), $15.2 million (Q3 2024), and $15.8 million (Q2 2024), per Business Quant data.